secwatch.observer — SEC 8-K summary
======================================

Issuer:     CytomX Therapeutics, Inc. (CTMX)
CIK:        0001501989
Form:       8-K
Filed at:   2026-06-22T20:52:39+00:00
Accession:  0001193125-26-277631
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CytomX shareholders approve charter amendment to double authorized common stock and equity plan increases
--------------------------------------------------------------------------------

- Charter Amendment increased authorized common stock from 300M to 600M shares, effective June 22, 2026.
- 2015 Plan Amendment adds 6.5M shares to equity incentive plan; ESPP Amendment adds 1M shares.
- Directors Matthew P. Young and Elaine V. Jones re-elected to Class II until 2029 Annual Meeting.
- Advisory vote on executive compensation passed (147.1M for, 1.7M against); company will hold Say-on-Pay annually.
- Ernst & Young LLP ratified as independent auditor for fiscal 2026 with 183M votes for.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501989/000119312526277631/0001193125-26-277631-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501989/000119312526277631/d154321d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-277631

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer